Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in adults with ulcerative pyoderma gangrenosum requiring systemic therapy
CTR20244695Phase 3Active
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of spesolimab in pyoderma gangrenosum (PG), sponsored by Boehringer Ingelheim. Started Jul 2025; status: active.
02
Drugs
spesolimab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on CTR20244695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244695.